New hope for deadly brain cancer? early trial launches
NCT ID NCT07455045
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called FZ-AD005 in 40 people with aggressive brain tumors (high-grade glioma) that have come back or not responded to treatment. The drug is designed to target and kill cancer cells while sparing healthy ones. The main goals are to find the safest dose and see if it can shrink or control the tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE MIDLINE GLIOMA (DMG) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Custom-Made vaccine train the immune system to fight brain cancer?
- Can a virus injected into brain tumors fight recurrence?
- Can adding lenvatinib to standard care outsmart a tough brain cancer?
- Can a pill reach the brain and fight tumors?
- Experimental brain cancer drug NRG-103 enters first human tests
- Targeted radiation delivered directly to brain tumor cavity in new trial